Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celldex Therapeutics, Inc. (CLDX : NSDQ)

• Company Description    CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. Number of Employees: 148

• Price / Volume Information    Yesterday's Closing Price: $32.13 Daily Weekly Monthly 20 Day Moving Average: 369,020 shares Shares Outstanding: 47.25 (millions) Market Capitalization: $1,518.22 (millions) Beta: 2.12 52 Week High: $48.40 52 Week Low: $19.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.03% -1.83% 12 Week -27.31% -32.52% Year To Date -27.91% -34.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 53 FRONTAGE ROAD SUITE 220 - HAMPTON,NJ 08827 USA ph: 908-200-7500 fax: 908-454-1911 ir@celldex.com http://www.celldex.com

• General Corporate Information    Officers Anthony S. Marucci - President; Chief Executive Officer and Director Karen L. Shoos - Chairman and Director Sam Martin - Senior Vice President;Chief Financial Officer and Keith L. Brownlie - Director Cheryl L. Cohen - Director Peer Information Celldex Therapeutics, Inc. (CORR.) Celldex Therapeutics, Inc. (RSPI) Celldex Therapeutics, Inc. (CGXP) Celldex Therapeutics, Inc. (BGEN) Celldex Therapeutics, Inc. (GTBP) Celldex Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117B202 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/14/23 Share - Related Items Shares Outstanding: 47.25 Most Recent Split Date: 2.00 (0.07:1) Beta: 2.12 Market Capitalization: $1,518.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.64 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.01 Price/Cash Flow: - Price / Sales: 481.97 EPS Growth vs. Year Ago Period: -26.53% vs. Previous Quarter: -10.71% Sales Growth vs. Year Ago Period: 455.75% vs. Previous Quarter: -40.05% ROE 03/31/23 - -32.84 12/31/22 - -28.90 09/30/22 - -25.47 ROA 03/31/23 - -30.35 12/31/22 - -26.77 09/30/22 - -23.72 Current Ratio 03/31/23 - 19.03 12/31/22 - 17.07 09/30/22 - 20.54 Quick Ratio 03/31/23 - 19.03 12/31/22 - 17.07 09/30/22 - 20.54 Operating Margin 03/31/23 - -3,490.86 12/31/22 - -4,397.58 09/30/22 - -9,035.47 Net Margin 03/31/23 - -3,766.22 12/31/22 - -4,765.59 09/30/22 - -9,840.85 Pre-Tax Margin 03/31/23 - -3,766.22 12/31/22 - -4,765.59 09/30/22 - -9,840.85 Book Value 03/31/23 - 6.41 12/31/22 - 6.93 09/30/22 - 7.39 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.01 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.79 09/30/22 - 0.00

Powered by Zacks Investment Research ©